Wall Street brokerages expect that Cerecor Inc (NASDAQ:CERC) will report sales of $5.45 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Cerecor’s earnings. The highest sales estimate is $5.60 million and the lowest is $5.30 million. The firm is expected to report its next earnings report on Thursday, February 13th.
According to Zacks, analysts expect that Cerecor will report full-year sales of $20.20 million for the current year. For the next fiscal year, analysts anticipate that the company will post sales of $22.80 million, with estimates ranging from $22.60 million to $23.00 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Cerecor.
Cerecor (NASDAQ:CERC) last announced its quarterly earnings data on Thursday, November 14th. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. The firm had revenue of $5.61 million for the quarter, compared to the consensus estimate of $5.15 million. Cerecor had a negative net margin of 113.66% and a negative return on equity of 121.32%.
A number of analysts recently commented on CERC shares. Maxim Group reiterated a “buy” rating and issued a $10.00 target price on shares of Cerecor in a research note on Friday, November 15th. ValuEngine downgraded Cerecor from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price target (up previously from $11.00) on shares of Cerecor in a report on Monday. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.00.
Shares of CERC stock traded up $0.08 during mid-day trading on Friday, hitting $3.63. 1,288 shares of the stock traded hands, compared to its average volume of 57,243. Cerecor has a 52-week low of $2.71 and a 52-week high of $7.65. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.71 and a current ratio of 0.73. The stock’s fifty day moving average is $3.36 and its two-hundred day moving average is $3.97.
In other news, major shareholder Armistice Capital Master Fund bought 2,200,000 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were acquired at an average cost of $3.05 per share, with a total value of $6,710,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Armistice Capital, Llc acquired 1,000,000 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was purchased at an average price of $2.95 per share, for a total transaction of $2,950,000.00. The disclosure for this purchase can be found here. Corporate insiders own 64.30% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. increased its stake in Cerecor by 4,046.6% in the 2nd quarter. BlackRock Inc. now owns 1,205,533 shares of the company’s stock worth $6,559,000 after acquiring an additional 1,176,460 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Cerecor by 56.5% during the 2nd quarter. Vanguard Group Inc. now owns 678,000 shares of the company’s stock valued at $3,689,000 after acquiring an additional 244,657 shares during the period. Wells Fargo & Company MN acquired a new stake in shares of Cerecor during the 2nd quarter valued at approximately $853,000. Northern Trust Corp boosted its stake in shares of Cerecor by 47.4% during the 2nd quarter. Northern Trust Corp now owns 55,971 shares of the company’s stock worth $304,000 after acquiring an additional 17,999 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Cerecor by 294.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 57,428 shares of the company’s stock worth $312,000 after acquiring an additional 42,885 shares in the last quarter. Institutional investors and hedge funds own 60.87% of the company’s stock.
Cerecor Company Profile
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.
Featured Story: How can investors find ex-dividend dates?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.